Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Neuropsychiatric disorders typically manifest as problems with attentional biases, aberrant learning, dysfunctional reward systems, and an absence of top-down cognitive control by the prefrontal cortex. In view of the cost of common mental health disorders, in terms of distress to the individual and family in addition to the financial cost to society and governments, new developments for treatments that address cognitive dysfunction should be a priority so that all members of society can flourish. Cognitive enhancing drugs, such as cholinesterase inhibitors and methylphenidate, are used as treatments for the cognitive symptoms of Alzheimer's disease and attention deficit hyperactivity disorder. However, these drugs and others, including modafinil, are being increasingly used by healthy people for enhancement purposes. Importantly for ethical and safety reasons, the drivers for this increasing lifestyle use of so-called smart drugs by healthy people should be considered and discussions must occur about how to ensure present and future pharmacological cognitive enhancers are used for the benefit of society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sears, D. O. (1986) · Journal of Personality and Social Psychology · doi:10.1037//0022-3514.51.3.515 · Cited by 2,119
A Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes
Wykes, T., Huddy, V., Cellard, C., McGurk, S. R., & Czobor, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10060855 · Cited by 1,693
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature
WILENS, T. E., ADLER, L. A., ADAMS, J., SGAMBATI, S., ROTROSEN, J., SAWTELLE, R., UTZINGER, L., & FUSILLO, S. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815a56f1 · Cited by 824
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Evaluating Dopamine Reward Pathway in ADHD: Clinical Implications
Volkow, N. D., Wang, G.-J., Kollins, S. H., Wigal, T. L., Newcorn, J. H., Telang, F., Fowler, J. S., Zhu, W., Logan, J., Ma, Y., et al. (2009) · JAMA · doi:10.1001/jama.2009.1308 · Cited by 728
del Campo, N., Chamberlain, S. R., Sahakian, B. J., & Robbins, T. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.036 · Cited by 685
Adrenergic pharmacology and cognition: Focus on the prefrontal cortex
Ramos, B. P., & Arnsten, A. F. T. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.006 · Cited by 641
Beddington, J., Cooper, C. L., Field, J., Goswami, U., Huppert, F. A., Jenkins, R., Jones, H. S., Kirkwood, T. B. L., Sahakian, B. J., & Thomas, S. M. (2008) · Nature · doi:10.1038/4551057a · Cited by 554
Self-citationA meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510
Cited by
Dou, K.-X., Tan, M.-S., Tan, C.-C., Cao, X.-P., Hou, X.-H., Guo, Q.-H., Tan, L., Mok, V., & Yu, J.-T. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0457-9 · Cited by 171
Cope, Z. A., Minassian, A., Kreitner, D., MacQueen, D. A., Milienne-Petiot, M., Geyer, M. A., Perry, W., & Young, J. W. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.031 · Cited by 27
“The potential pro-cognitive effects of moda fi nil are unlikely to be limited to one domain, (Minzenberg and Carter, 2008; Sahakian and Morein-Zamir, 2015), hence others remain to be tested.”
InfluentialStimulants, cognition and ADHD
Baroni, A., & Castellanos, F. X. (2015) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2015.04.010 · Cited by 14
“In this brief review, we will suggest that understanding how and for whom such benefits may accrue will require construing cognition more broadly, to encompass such domains as motivation and emotion regulation [11 ,15,16,17 ].”
Background
Metadata
- Authors
- Sahakian, B. J., & Morein-Zamir, S.
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 2
- Issue
- 4
- Pages
- 357-362
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W2154228420
- Cited by
- 54
- References
- 17
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people. https://app.cochat.ai/papers/10.1016/s2215-0366(15)00004-8
- The paper
- Sahakian, B. J., & Morein-Zamir, S. (2015). Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(15)00004-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.